Short answer
HAEMONETICS CORP (HAE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Haemonetics announced fiscal 2027 second-quarter and first-half financial results.
HAEMONETICS CORP 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Haemonetics announced fiscal 2027 second-quarter and first-half financial results
- Results cover the quarter ended September 26, 2026
- Full financial details are in Exhibit 99.1, the company’s earnings press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 FY27 revenue $357.8M, up 9.3%, with organic growth 10.0%, signaling broad operating momentum
- Apheresis led growth at 12.6% reported and 13.6% organic, while MedSurg delivered 5.1% reported growth
- GAAP operating margin expanded to 21.0% from 17.9%; adjusted margin declined to 26.3% from 26.7% amid higher personnel and freight costs
- Adjusted EPS $1.35, up 6.3%; operating cash flow $128.1M and free cash flow $103.8M
- FY27 organic revenue guidance raised to 6%-9% from 4%-7%, while adjusted margin guidance narrowed to 0-50 basis points expansion### Sources:
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HAEMONETICS CORP 8-K filings
Get the next HAE 8-K as it lands
Follow HAE for push alerts, or ask the research agent what this filing means.